OncoTherapy Science, Inc.

Tokyo Stock Exchange 4564.T

OncoTherapy Science, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 10.23

OncoTherapy Science, Inc. Price to Sales Ratio (P/S) is 10.23 on January 14, 2025, a 141.91% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

OncoTherapy Science, Inc. 52-week high Price to Sales Ratio (P/S) is 27.00 on August 08, 2024, which is 163.81% above the current Price to Sales Ratio (P/S).
OncoTherapy Science, Inc. 52-week low Price to Sales Ratio (P/S) is 3.50 on February 13, 2024, which is -65.76% below the current Price to Sales Ratio (P/S).
OncoTherapy Science, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 11.74.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Tokyo Stock Exchange: 4564.T

OncoTherapy Science, Inc.

CEO	Mr. Junichi Shimada
IPO Date	Sept. 29, 2005
Location	Japan
Headquarters	3-2-1 Sakado
Employees	54
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials Research & Consulting

Description

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.

Key trends

Past 5 years